ArticleJCO precision oncology2021
Comprehensive Clinical and Molecular Characterization of
Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis.The oncologist · 2026Pooled it
- KRAS G12C inhibitors in KRASFrontiers in immunology · 2026Pooled it
- Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.The oncologist · 2023Pooled it
- Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Signal transduction and targeted therapy · 2025Trial
- Adagrasib with or without Cetuximab in Colorectal Cancer with MutatedThe New England journal of medicine · 2023Trial
- Oncogene-Mechanics Axis: KRAS G12C Confers Agility Enabling Malignant Mechano-responses to Peristalsis in Colorectal Cancer.bioRxiv : the preprint server for biology · 2026Article
- Context defines precision: rethinking KRAS inhibition in oncology.NPJ precision oncology · 2026Review
- A New Era of Salvage-Line Treatment for Metastatic Colorectal Cancer: The Role and Clinical Significance of Circulating Tumor DNA.Biomolecules · 2026Review
- Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances.Molecular biomedicine · 2026Review
- Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs.Molecular cancer · 2025Review
- Article
- Differential Response and Resistance to KRAS-Targeted Therapy.Molecular carcinogenesis · 2025Review
- Current Status of Precision Medicine in Colorectal Cancer in Japan.International journal of molecular sciences · 2025Review
- A Narrative Review of RAS Mutations in Early-Stage Colorectal Cancer: Mechanisms and Clinical Implications.Medicina (Kaunas, Lithuania) · 2025Review
- Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm.Nature reviews. Clinical oncology · 2025Review
- TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer.World journal of gastrointestinal oncology · 2024Review
- TargetingInternational journal of molecular sciences · 2024Review
- Engineered a dual-targeting HA-TPP/A nanoparticle for combination therapy againstBioactive materials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 2 institutions in 1 country.
Funding
Abstract
purpose
methodsWe queried the MD Anderson Cancer Center data set for patients with colorectal cancer who harbored
resultsAmong the 4,632 patients with comprehensive molecular profiling, 134 (2.9%) were found to have
conclusionPFS is poor for patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.